Neurmedix, Inc.

Cymabay Therapeutics, Inc.

Laurus Labs Private Limited

Metabolex, Inc.

Harbor Therapeutics, Inc.

S.s.c.i., Inc.

Aptuit (kansas City), LLC

Igor Ivanisevic

Mark Andres

Kyle Stephens

Steven K White

Brenton Skylar Wolfe

Patricia Andres

Charles A McWherter

Jiangao Song

Ekaterina Albert

Fang Ma

Barbara C Stahly

Donald R Hallenbeck

Simon Bates

David E Bugay

Masna Mahesh

Gottumukkala V Subbaraju

Hindupur R Mohan

Thatipally Suresh

Charles A Mcwherter

Brenton Wolf

Described herein are solid state 17&#x3b1;-ethynylandrost-5-ene-3&#x3b2;,7&#x3b2;,17&#x3b2;-triol including amorphous and crystalline forms and specific polymorphic forms thereof, and use of solid state 17&#x3b1;-ethynylandrost-5-ene-3&#x3b2;,7&#x3b2;,17&#x3b2;-triol in treating numerous diseases and disorders, including hyperglycemic conditions, such as type 2 diabetes and metabolic syndrome, autoimmune conditions, such as rheumatoid arthritis, ulcerative colitis and type 1 diabetes, among other inflammation related conditions, and neurodegenerative conditions in subjects or human patients.

Crystalline solvate forms of a pharmaceutical

The invention provides and describes solid state 17&#x3b1;-ethynyl-androst-5-ene-3&#x3b2;, 7&#x3b2;,17&#x3b2;-triol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17&#x3b1;-ethynyl-androst-5-ene-3&#x3b2;, 7&#x3b2;,17&#x3b2;-triol include Form I anhydrate and Form IV and Form V solvates. The invention further relates to solid and suspension formulations containing 17&#x3b1;-ethynyl-androst-5-ene-3&#x3b2;,7&#x3b2;,17&#x3b2;-triol in a described solid state form and use of the formulations to treat hyperglycemic conditions, such as type 2 diabetes and metabolic syndrome, and autoimmune conditions, such as rheumatoid arthritis, ulcerative colitis and type 1 diabetes, among other inflammation related conditions in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17&#x3b1;-ethynyl-androst-5-ene-3&#x3b2;, 7&#x3b2;,17&#x3b2;-triol and uses of such formulations in treating the described conditions.

Treatment methods using pharmaceutical solid state forms

The invention provides and describes solid state 17&#x3b1;-ethynyl-androst-5-ene-3&#x3b2;,7&#x3b2;,17&#x3b2;-triol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17&#x3b1;-ethynyl-androst-5-ene-3&#x3b2;,7&#x3b2;,17&#x3b2;-triol include Form I anhydrate and Form IV and Form V solvates. The invention further relates to solid and suspension formulations containing 17&#x3b1;-ethynyl-androst-5-ene-3&#x3b2;,7&#x3b2;,17&#x3b2;-triol in a described solid state form and use of the formulations to treat hyperglycemic conditions, such as type 2 diabetes and metabolic syndrome, and autoimmune conditions, such as rheumatoid arthritis, ulcerative colitis and type 1 diabetes, among other inflammation related conditions in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17&#x3b1;-ethynyl-androst-5-ene-3&#x3b2;,7&#x3b2;,17&#x3b2;-triol and uses of such formulations in treating the described conditions.

Crystalline anhydrate forms of a pharmaceutical

Crystalline salts of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine, compositions thereof, methods for their preparation, and methods for their use are disclosed.

Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts

The present invention provides a scalable process for the preparation of stilbenes by (i) condensing 3,5-dialkylbenzyl phosphonates with 4'-O-tetrahydropyranyl benzaldehyde to get 3,5-alkyl-4&#x2032;-O-tetrahydropyranyl Stilbene and (ii) deprotecting the obtained 3,5-Dialkyl-4&#x2032;-O-tetrahydropyranylstilbene to yield stilbenes. The present invention also provides a novel intermediate 3,5-Dialkyl-4&#x2032;-O-tetrahydropyranyl stilbene, which is a key intermediate for the synthesis of stilbenes such as Pterostilbene and Resveratrol. The present invention also provides characteristics of various solid forms of Pterostilbene, methods for their preparation, as well as dosage forms containing the same for administration to or consumption by humans.

Key intermediate for the preparation of Stilbenes, solid forms of Pterostilbene, and methods for making the same

The invention provides and describes solid state 17&#x3b1;-ethynyl-androst-5-ene-3&#x3b2;, 7&#x3b2;,17&#x3b2;-triol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17&#x3b1;-ethynyl-androst-5-ene-3&#x3b2;, &#x3b2;,17&#x3b2;-triol include Form I anhydrate and Form IV and Form V solvates. The invention further relates to solid and suspension formulations containing 17&#x3b1;-ethynyl-androst-5-ene-3&#x3b2;,7&#x3b2;,17&#x3b2;-triol in a described solid state form and use of the formulations to treat hyperglycemic conditions, such as type 2 diabetes and metabolic syndrome, and autoimmune conditions, such as rheumatoid arthritis, ulcerative colitis and type 1 diabetes, among other inflammation related conditions in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17&#x3b1;-ethynyl-androst-5-ene-3&#x3b2;, 7&#x3b2;,17&#x3b2;-triol and uses of such formulations in treating the described conditions.

Solid state forms of a pharmaceutical

A method of analyzing patterns. The method comprises: receiving a first diffraction pattern; receiving a second diffraction pattern; receiving a third diffraction pattern; determining a similarity between the first and second diffraction patterns; determining a similarity between the first and third diffraction pattern; determining a similarity between the second and third diffraction pattern; and performing hierarchical cluster analysis on the first and second diffraction pattern based on the determined similarity.

System and method for matching diffraction patterns

Growing community of inventors

West Lafayette, IN, United States of America

Igor Ivanisevic